Niagen Bioscience Earnings Call Highlights Growth Push

Niagen Bioscience, Inc. ((NAGE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Niagen Bioscience’s latest earnings call carried a cautiously upbeat tone, with management underscoring steady revenue growth, resilient margins, and a fortress balance sheet. At the same time, executives acknowledged near‑term pressures from channel volatility, higher spending, and intensifying competition, especially around NMN products and regulatory uncertainty.

Revenue and Profitability

Niagen reported total revenue of $31.5 million, or $31.1 million excluding divested reference standards, marking 5% year‑over‑year growth on a comparable basis. Net income climbed to $6.3 million, translating to diluted earnings per share of $0.08 versus $0.07 in the prior year, signaling incremental operating leverage despite rising costs.

Strong E‑commerce Growth

Digital channels remain the key engine, with core e‑commerce rising 14% year over year and TRU NIAGEN online sales reaching $19.2 million, up $2.4 million. Management noted that its direct‑to‑consumer website is growing roughly twice as fast as Amazon, suggesting better brand control and higher‑value customer relationships.

Ingredient Sales and Mix

NIAGEN ingredient revenue increased 2% to $8.2 million, including $7.3 million from food‑grade and $0.85 million from pharma‑grade sales. This mix reflects broader business‑to‑business demand across nutrition and emerging pharmaceutical applications, reinforcing the company’s dual consumer and ingredient model.

Margins and Balance Sheet Strength

Gross margin ticked up to 63.5%, a 10‑basis‑point improvement year over year, showing pricing and cost discipline even as competition heats up. The company ended the quarter with $66.5 million in cash, no debt, and roughly $82.3 million of working capital, providing ample financial flexibility for investment and buybacks.

Product Launch Momentum: Niagen Plus and NanoCloud

Niagen Plus, an at‑home injection kit paired with telehealth, launched with strong initial web traffic, healthy conversions, and positive early user feedback. The company also pilot‑launched Niagen NanoCloud skincare, which nearly sold out and delivered favorable consumer survey results ahead of a broader rollout planned for October.

Regulatory and Quality Edge with USP Monograph

Management highlighted a major quality milestone as NIAGEN (NR chloride) secured a published USP dietary supplement ingredient monograph. This rare benchmark in the supplement industry gives Niagen a powerful differentiation tool versus generic rivals, particularly as quality scrutiny and regulatory risk rise.

Clinical and Scientific Leadership

The company continued to invest in science, sponsoring the NAD for Health meeting and spotlighting research on tissue NAD levels, potential benefits of IV and injection routes, and synergies with exercise. Niagen is also progressing toward IND‑enabling preclinical work targeting rare orphan indications such as ataxia telangiectasia, opening optionality beyond supplements.

Expanding Commercial Footprint

NIAGEN is now available in roughly 1,200 clinics for IV offerings, with strong order and repeat rates indicating good practitioner and patient reception. Management is in talks with two major skincare brands and planning broader international and selective retail distribution, signaling an expanding multi‑channel footprint.

Customer and B2B Channel Pressure

Two key customers ordered less than a year ago, weighing on top‑line growth and offsetting robust e‑commerce trends. In addition, sales to Watsons and other B2B distributors fell by about $1.5 million year over year due to timing and inventory management, and management warned that these orders will likely remain lumpy.

Operating Cash Flow and Investment Spending

Operating cash flow swung to a $1.2 million use of cash from $7.9 million provided a year ago, driven mainly by a $3.6 million inventory build and timing of collections, including a large partner balance since recovered. Selling and marketing expense rose to 30.7% of net sales from 26.6%, while G&A and R&D also increased as the company leans into brand and clinical investments.

Competitive and Regulatory Headwinds

Following the FDA’s NMN reversal, more than 300 NMN stock‑keeping units have flooded Amazon, pushing up keyword bidding costs and making new customer acquisition more expensive and price sensitive. Niagen has challenged the agency’s NMN stance in court, and management acknowledged that the ongoing legal process keeps regulatory uncertainty elevated for the entire category.

Geographic Limits for New Injectables

The rollout of the Niagen Plus at‑home injection kit is constrained by pharmacy licensing issues that currently restrict availability in California. Management expects this hurdle to be cleared in the coming weeks, but the constraint temporarily caps the addressable market for what could become a meaningful growth driver.

Forward‑Looking Guidance and Capital Allocation

Management reaffirmed its full‑year 2026 revenue growth outlook of 10% to 15%, with e‑commerce as the primary driver and new product launches providing potential upside. They plan to keep increasing selling and marketing spend, see G&A up $3 million to $4 million year over year, continue their $20 million share repurchase program, and expect inventory to decline and cash generation to improve even as partner order timing remains uneven.

Niagen Bioscience’s call painted the picture of a company balancing disciplined profitability with aggressive investment in brand, science, and new formats. Investors will be watching whether e‑commerce momentum, product innovation, and regulatory differentiation can outpace channel volatility and NMN‑driven competition, but for now management’s confidence in its growth trajectory remains intact.